Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Shaji Kumar, Natalie S. Callander, Kehinde Adekola, +32

Journal of the National Comprehensive Cancer Network

Hematological MalignancyRelapsed/refractory MmMedicineMalignant Blood DisorderHematology +13

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Susan Bal, Myo Htut, Omar Nadeem, +17

Blood

Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.

Shaji Kumar, Natalie S. Callander, Kehinde Adekola, +26

PubMed

Translational MedicineAlzheimer's DiseaseMedicineAmyloid FibrilsVersion 2.2023 +9

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis

Michael Rainone, Dat Ngo, John H. Baird, +4

Blood Advances

Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma

Sundar Jagannath, Thomas G. Martin, Yi Lin, +28

Journal of Clinical Oncology

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Susan Bal, Mehmet H. Kocoglu, Omar Nadeem, +12

Blood

Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM).

Doris K. Hansen, Krina K. Patel, Lauren C. Peres, +17

Journal of Clinical Oncology

Hematological MalignancyOncologyHealth SciencesCiltacabtagene AutoleucelIntended Soc Cilta-cel +13

Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)

Susan Bal, Larry D. Anderson, Omar Nadeem, +17

Blood

Ethical challenges with CAR T slot allocation with idecabtagene vicleucel manufacturing access.

Taxiarchis Kourelis, Radhika Bansal, Krina K. Patel, +14

Journal of Clinical Oncology

Primary CareOncologyE20021 BackgroundHealth PolicyIdecabtagene Vicleucel +11

Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI.

Saad Z. Usmani, Thomas Martin, Jesús G. Berdeja, +17

Journal of Clinical Oncology

Ciltacabtagene AutoleucelImmunologyImmunoeditingPharmacotherapyImmunotherapeutics +15